国内老年痴呆患者已超千万!礼来阿尔茨海默病新药在华获批,商业化前景几何?

时代财经
18 Dec 2024

本文来源:时代财经 作者:张羽岐图片来源:图虫创意成功闯关美国5个月后,礼来制药的阿尔茨海默病(AD)新药在中国获批。12月18日,礼来对外宣布,其旗下阿尔茨海默病疗法多奈单抗注射液(Donanemab,中文商品名:记能达)获得中国国家药品监督管理局批准上市,用于治疗成人因阿尔茨海默病引起的轻度认知功能障碍和阿尔茨海默病轻度痴呆。该药每四周静脉注射一次,前三次剂量为700毫克/次,随后为1400...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10